Leuprorelin lowers QOL initially in endometriosis

&NA;

doi:10.2165/00128413-200012520-00011

Leuprorelin lowers QOL initially in endometriosis

&NA;

In: Inpharma Weekly · 2000 · vol. &NA;(1252) , pp. 5 · doi:10.2165/00128413-200012520-00011 · W4242064205

article OA: closed CC0

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex

⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This paper investigated the impact of leuprorelin on quality of life in patients with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: A double-blind, randomized, placebo-controlled trial 2000

References (1)

Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: A double-blind, randomized, placebo-controlled trial via openalex

Source provenance

openalex: last seen: 2026-06-10T17:14:06.276822+00:00

License: CC0 · commercial use OK

[1] Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: A double-blind, randomized, placebo-controlled trial 2000